Apogenix Enrolls First Patients in Pivotal Phase III Trial for the Treatment of Hospitalized COVID-19 Patients with Asunercept
- The ASUCOV trial assesses efficacy and safety of asunercept on top of standard of care
- Over 600 patients to be enrolled at 50 trial sites in Europe, India, and South Africa
- Trial funded by the German Federal Government and dievini Hopp BioTech
Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that the first patients have been enrolled in a pivotal phase III trial to investigate the efficacy and safety of asunercept on top of standard of care (SoC) for the treatment of hospitalized patients with moderate to severe COVID-19 disease (ASUCOV; NCT05639192). The multicenter, double-blind, placebo-controlled trial aims to enroll more than 600 hospitalized patients requiring oxygen in nine different countries.